Novartis taps into Ionis’ cardiovascular drugs – PharmaTimes

PharmaTimesNovartis taps into Ionis’ cardiovascular drugsPharmaTimesAccording to Novartis, the two investigational antisense therapies being developed by Ionis – AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx – have the potential to lower both lipoproteins up to 90 percent and “significantly reduce cardiovascular risk in …Ionis Pharmaceuticals Inc (IONS), Akcea Strike Favorable Deal with Novartis AG (ADR) (NVS): Cowen Top AnalystSmarter AnalystIonis and Akcea Enter into Strategic Collaboration with Global …PR Newswire (press release)Ionis and subsidiary Akcea collaborate with Novartis to develop two cardiovascular candidates in deal valued as high …Seeking Alphaall 19 news articles »

Read More

Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting – TheStreet.com

Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile VomitingTheStreet.comThanks, Michael. For months, Yee has been pounding the table, urging investors to pay attention to a promising but under-the-radar antisense therapy from Ionis Pharmaceuticals (IONS) known as IONIS-DMPK to treat a rare, inherited muscle-wasting disease.Ionis’ candidate for muscle wasting disease flunks mid-stage study; shares off 6%Seeking Alphaall 2 news articles »

Read More

Breaking Short Interest: After Reaching Milestone, Is Bio Path Holdings DE (NASDAQ:BPTH)’s Short Interest Revealing … – Post News

Post NewsBreaking Short Interest: After Reaching Milestone, Is Bio Path Holdings DE (NASDAQ:BPTH)’s Short Interest Revealing …Post NewsBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The company has a market cap of $114.24 million. The Firm utilizes a technology that achieves systemic delivery for target specific protein …Bio-Path Holdings Inc. (BPTH) Plunges 7.41% on January 03 …Equities.comall 10 news articles »

Read More

Stocks: Bio-Path Holdings Inc. (BPTH) Stock Rating Decreased by the Zacks Investment Research – DailyQuint

Stocks: Bio-Path Holdings Inc. (BPTH) Stock Rating Decreased by the Zacks Investment ResearchDailyQuint… antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology …and more »

Read More

Momentum Stocks in Focus: Sarepta Therapeutics, Inc. (SRPT), Carnival Corporation (CCL), KKR & Co. L.P. (KKR) – iStreetWire

iStreetWireMomentum Stocks in Focus: Sarepta Therapeutics, Inc. (SRPT), Carnival Corporation (CCL), KKR & Co. L.P. (KKR)iStreetWireThe company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic …and more »

Read More

Ionis’ Antisense Technology Claims A Brief Period Of Success – Seeking Alpha

Seeking AlphaIonis’ Antisense Technology Claims A Brief Period Of SuccessSeeking AlphaIonis Pharmaceuticals announced on December 23, 2016, the FDA has approved SPINRAZA (Nusineren), an intratechal formulation of an antisense oligonucleotide for the treatment of SMA in pediatric and adult patients. Ionis Pharmaceuticals is eligible to …AveXis hit as Biogen becomes first to market SMA medFierceBiotechFDA guides approval of Ionis and Biogen’s new SMA therapyMedCity NewsSPINRAZA™ (nusinersen) Approved in US to Treat Broad Range of Patients with Spinal Muscular AtrophyPharmiWeb.com (press release)Clinical Leader -Investor’s Business Dailyall 87 news articles »

Read More

AveXis hit as Biogen becomes first to market SMA med – FierceBiotech

FierceBiotechAveXis hit as Biogen becomes first to market SMA medFierceBiotechOn the safety side, Leerink said: “[These] likely stem from safety events seen in other antisense oligonucleotide programs such as Kynamro and potentially volanesorsen and IONIS-TTRrx. We caught up with Ionis who notes that no patient on nusinersen had …FDA guides approval of Ionis and Biogen’s new SMA therapyMedCity NewsIonis announces FDA approval of first SMA drug in the U.S for pediatric and adult patientsNews-Medical.netUS FDA Approves Biogen’s SPINRAZA (nusinersen), The First Treatment For Spinal Muscular AtrophyClinical LeaderBenzinga -Nasdaq -Biogen Mediaall 80 news articles »

Read More

The FDA’s Christmas Breakthrough – Forbes

ForbesThe FDA’s Christmas BreakthroughForbesThere were also more lung infections among patients treated with Spinraza than a control group. Investors may worry that these side effects could extend to other medicines Ionis is developing, all of which use a technology called antisense that stops …U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First …Business Wire (press release)FDA OKs Nusinersen, First Drug for Spinal Muscular AtrophyMedscapeIONS Scripts History, PTLA Gets FDA Date, Strongbridge Slumps, NEOT On WatchNasdaqNews-Medical.net -Rare Disease Report -Austrian Tribuneall 217 news articles »

Read More

FDA approves Ionis spinal muscular atrophy drug Spinraza – The San Diego Union-Tribune

The San Diego Union-TribuneFDA approves Ionis spinal muscular atrophy drug SpinrazaThe San Diego Union-TribuneIt was developed with Ionis’ antisense technology, which alters how the genetic instructions coded in DNA are translated into proteins. All Ionis drugs use antisense. “What it says is once again that antisense works, that it can do things no other …The FDA’s Christmas BreakthroughForbesU.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First …Business Wire (press release)FDA OKs Nusinersen, First Drug for Spinal Muscular AtrophyMedscapeNasdaq -News-Medical.netall 210 news articles »

Read More

SPINRAZA™ (nusinersen) Approved in US to Treat Broad Range of Patients with Spinal Muscular – PR Newswire (press release)

SPINRAZA™ (nusinersen) Approved in US to Treat Broad Range of Patients with Spinal MuscularPR Newswire (press release)We are proud that SPINRAZA exists because Ionis created and validated a new platform for drug discovery, antisense technology,” said Stanley T. Crooke, M.D., Ph.D., chief executive officer and chairman of Ionis. “We want to thank the families …

Read More

Blog Coverage Ionis Pharma Records Three Milestones Payment Within a Week – Yahoo Sports

The Cerbat GemBlog Coverage Ionis Pharma Records Three Milestones Payment Within a WeekYahoo SportsEarlier this year, we earned $10 million when Janssen licensed IONIS-JBI1-2.5Rx, an orally delivered antisense drug for the treatment of a GI autoimmune disease. The program announced today marks the second to advance under our collaboration with …Ionis Pharmaceuticals Earns Milestone Payment from Janssen for …PR Newswire (press release)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Rises, Analysts: Hold RatingReview FortuneIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Recommendations and Insider TradingThe Independent RepublicSeeking Alpha -KC Registerall 20 news articles »

Read More

Blog Coverage Ionis Pharma Records Three Milestones Payment Within a Week – Yahoo Finance

The Cerbat GemBlog Coverage Ionis Pharma Records Three Milestones Payment Within a WeekYahoo FinanceEarlier this year, we earned $10 million when Janssen licensed IONIS-JBI1-2.5Rx, an orally delivered antisense drug for the treatment of a GI autoimmune disease. The program announced today marks the second to advance under our collaboration with …Ionis Receives $5 Million Milestone from J&J Unit for GI DrugNasdaqIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Recommendations and Insider TradingThe Independent Republicall 20 news articles »

Read More

Ionis Pharmaceuticals Earns Milestone Payment from Janssen for … – PR Newswire (press release)

Smarter AnalystIonis Pharmaceuticals Earns Milestone Payment from Janssen for …PR Newswire (press release)CARLSBAD, Calif., Dec. 22, 2016 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned $5 million milestone …Stock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Earns Milestone Payment from Janssen for Advancing a …Smarter AnalystIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Rises, Analysts: Hold RatingReview FortuneIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Recommendations and Insider TradingThe Independent RepublicSeeking Alphaall 10 news articles »

Read More

Ionis Pharma, AstraZeneca advance first generation 2.5 LICA drug into preclinical development to treat … – pharmabiz.com

TRAIonis Pharma, AstraZeneca advance first generation 2.5 LICA drug into preclinical development to treat …pharmabiz.comAZD8233 is designed to inhibit an undisclosed target to treat cardiovascular disease and is also the first of a new class of antisense drugs that uses both Ionis’ proprietary Generation 2.5 chemistry and its LIgand Conjugated Antisense or LICA technology.Patience Rewards Ionis And ZiarcoSeeking AlphaAstraZeneca uses Ionis to make sense from antisenseBioPharma DiveIonis Pharmaceuticals Inc (IONS) Files Form 4 Insider Selling : B Lynne Parshall Sells 4000 SharesMarket Digestall 21 news articles »

Read More

Stock Mover of The Day: 1.92 is Bio-path Holdings Inc’s (NASDAQ … – Post News

Post NewsStock Mover of The Day: 1.92 is Bio-path Holdings Inc’s (NASDAQ …Post NewsBio-path Holdings Inc (NASDAQ:BPTH) institutional sentiment decreased to 1.92 in 2016 Q3. Its down -0.75, from 2.67 in 2016Q2. The ratio has worsened, as 25 …Bio-Path Holdings Inc. (BPTH) Downgraded by Zacks Investment …Sports PerspectivesBio-Path Holdings Inc. (BPTH) Moves Higher on Volume Spike for …Equities.comZacks Investment Research downgraded Bio-Path Holdings Inc …Breaking Finance Newsall 6 news articles »

Read More